In a double-blind placebo controlled trial intranasal NPC 567, a bradykinin antagonist, failed to alleviate the symptoms of experimental rhinovirus colds. Indeed, there was evidence that the drug enhanced the symptoms although no irritant effect was detected on the uninfected nasal mucosa. Rhinovirus; Bradykinin antagonist (NPC 567); Human volunteer Correspondence to. P.G. Higgins, MRC Common Cold Unit, Harvard Hospital, Salisbury, Wiltshire SP2 8BW, U.K. 0166-3542/90/$03.50 